Galecto (GLTO) Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025 summary

Strategic review and pipeline enhancement

• Completed a strategic review, leading to an enhanced oncology-focused pipeline and acquisition of BRM-1420 for AML.

• BRM-1420 is a novel dual ENL-YEATS and FLT3 inhibitor with promising preclinical anti-tumor activity and potential to address menin inhibitor resistance.

• Early data supports drug activity in ENL-YEATS inhibition, covering over 30% of AML population.

• Cash runway extends into 2026, supporting IND for the AML program.

BRM-1420 asset and preclinical data

• BRM-1420 shows superior efficacy to existing FLT3 and menin inhibitors in preclinical AML models.

• Demonstrates synergy with standard of care and is positioned for combination therapies.

• Covers high-risk AML genetic drivers, including KMT2A, NPM1, and FLT3, with potential for broader patient coverage due to co-mutations.

• Preclinical studies show rapid, durable responses, cell cycle arrest, and improved safety profile without QTc liability.

• Demonstrated significant tumor reduction and improved survival in mouse models compared to leading competitors.

Mechanism of action and resistance

• Targets ENL-YEATS, downstream of menin, potentially effective in menin-resistant AML due to MEN1 mutations.

• Preclinical data shows activity in patient-derived cell lines with TET2, c-KIT, ASXL1, RUNX1, and TP53 mutations.

• In vitro studies indicate additive or synergistic effects with azacitidine, FLT3 inhibitors, venetoclax, and menin inhibitors.

• No observed QTc prolongation or major toxicity in animal studies; mild, manageable hematologic effects noted.